

Malawi

Support for Vaccine: HPV This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Malawi						$= \mu_i r_{ij}$
2.	Vaccine gran	Vaccine grant number: 18-MWI-08f-Y, 19-MWI-08f-Y, 1921-MWI-19b-X						
3.	Date of Decision Letter: 10 September 2019							
4.	Date of the F	artnership Fra	ramework Agreement:		29	29 October 2013		
5.	Programme	title:	New Vaccine Support (NVS), HPV, Routine					
6.	Vaccine type:		HPV					
7.	Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID							
8.	Programme Duration: 2019-2021							
9.	Programme Budget (indicative): ² (subject to the terms of the Partnership Framework Agreement, if applicable)							
		2019	2020	2021	2022	2023	2024	Total ²
	Programme Budget (US\$)	2,243,000	2,327,500	2,015,500	-		(Pale 1	6,586,000
10.	Vaccine intro	oduction grant	t			F 7 - 1		
				Approval		e de la junto de		
	Year		Grant Number		Amount (US\$)			
		2019	19- MW	-08f-Y		674,500		

11. Product switch grant

Not applicable

12. Indicative Annual Amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi		
funds	2019	2020
Number of vaccine doses	493,700	511,200
Annual Amounts (US\$)	2,243,000	2,327,500

3 This is the amount that Gavi has approved.

¹ This is the entire duration of the programme.
² This is the total amount endorsed by Gavi for the entire duration of the programme.



13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to

UNICEF.

Not applicable 14. Self-procurement:

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:

Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021
Number of vaccine doses	23,500	20,500
Number of AD syringes	-	
Number of re-constitution syringes	-	_
Number of safety boxes		
Value of vaccine doses (US\$)	105,701	91,922
Total co-financing payments (US\$) (including freight)	107,000	93,000

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

		Due dates
	for the annual procurement of vaccines, Country shall submit the ormation each year:	ingrodetis, Abone S
•	vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	erach se mid
	ce with applicable Gavi processes, Country shall report on tic and financial performance.	To be agreed with Gavi Secretariat



18.	Financial clarifications:		
	Not applicable		
19.	Other conditions:		
	Not applicable		

Signed by,

On behalf of Gavi

Thabani Maphosa,

Managing Director, Country Programmes

10 September 2019